Economic dimensions of personalized and precision medicine /:
Personalized and precision medicine (PPM) - the targeting of therapies according to an individual's genetic, environmental, or lifestyle characteristics - is becoming an increasingly important approach in health care treatment and prevention. This volume explores the intersection of the scienti...
Gespeichert in:
| Weitere Verfasser: | , , |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Chicago ; London :
The University of Chicago Press,
2019.
|
| Schriftenreihe: | National Bureau of Economic Research conference report.
|
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Zusammenfassung: | Personalized and precision medicine (PPM) - the targeting of therapies according to an individual's genetic, environmental, or lifestyle characteristics - is becoming an increasingly important approach in health care treatment and prevention. This volume explores the intersection of the scientific, clinical, and economic factors affecting the development of PPM, including its effects on the drug pipeline, on reimbursement of PPM diagnostics and treatments, and on funding of the requisite underlying research; and it examines recent empirical applications of PPM. |
| Beschreibung: | 1 online resource |
| Bibliographie: | Includes bibliographical references and index. |
| ISBN: | 9780226611235 022661123X |
Internformat
MARC
| LEADER | 00000cam a2200000 i 4500 | ||
|---|---|---|---|
| 001 | ZDB-4-EBA-on1090397075 | ||
| 003 | OCoLC | ||
| 005 | 20241004212047.0 | ||
| 006 | m o d | ||
| 007 | cr cnu---unuuu | ||
| 008 | 190322t20192019ilu ob 001 0 eng d | ||
| 040 | |a N$T |b eng |e rda |e pn |c N$T |d N$T |d EBLCP |d UKMGB |d YDXIT |d UKAHL |d STBDS |d OCLCQ |d DEGRU |d OCLCQ |d BRX |d OCLCO |d SFB |d OCLCQ |d OCLCO |d OCLCQ |d OCLCF |d OCLCA |d OCLCQ |d OCLCA |d OCLCO |d OCLCL |d OCLCA |d OCLCL |d OCLCQ |d DXU | ||
| 015 | |a GBB970705 |2 bnb | ||
| 016 | 7 | |a 019360804 |2 Uk | |
| 019 | |a 1298410401 |a 1370503711 | ||
| 020 | |a 9780226611235 |q (electronic book) | ||
| 020 | |a 022661123X |q (electronic book) | ||
| 020 | |z 9780226611068 | ||
| 020 | |z 022661106X | ||
| 035 | |a (OCoLC)1090397075 |z (OCoLC)1298410401 |z (OCoLC)1370503711 | ||
| 037 | |a org.bibliovault.9780226611235 |b BiblioVault | ||
| 043 | |a n-us--- | ||
| 050 | 4 | |a RM301.3.G45 |b E265 2019 | |
| 060 | 4 | |a 2019 H-417 | |
| 060 | 4 | |a WB 102.7 | |
| 072 | 7 | |a MED |x 071000 |2 bisacsh | |
| 082 | 7 | |a 615.7 |2 23 | |
| 084 | |a QX 700 |2 rvk |0 (DE-625)rvk/142186 | ||
| 049 | |a MAIN | ||
| 245 | 0 | 0 | |a Economic dimensions of personalized and precision medicine / |c edited by Ernst R. Berndt, Dana Goldman, and John Rowe. |
| 264 | 1 | |a Chicago ; |a London : |b The University of Chicago Press, |c 2019. | |
| 264 | 4 | |c ©2019 | |
| 300 | |a 1 online resource | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 490 | 1 | |a National Bureau of Economic Research conference report | |
| 504 | |a Includes bibliographical references and index. | ||
| 505 | 0 | |a Intro; Contents; Acknowledgment; Introduction / Ernst R. Berndt, Dana P. Goldman, and John W. Rowe; 1. The Economic Value and Pricing of Personalized Medicine / Tomas J. Philipson; 2. Therapeutic Translation of Genomic Science: Opportunities and Limitations of GWAS / Manuel Hermosilla and Jorge Lemus; 3. The Value of Pharmacogenomic Information / John A. Graves, Zilu Zhou, Shawn Garbett, and Josh F. Peterson; 4. The Information Pharms Race and Competitive Dynamics of Precision Medicine: Insights from Game Theory / Ernst R. Berndt and Mark R. Trusheim | |
| 505 | 8 | |a 5. Characterizing the Drug Development Pipeline for Precision Medicines / Amitabh Chandra, Craig Garthwaite, and Ariel Dora Stern6. Cost Sharing in Insurance Coverage for Precision Medicine / Mark V. Pauly; 7. Measuring the Potential Health Impact of Personalized Medicine: Evidence from Multiple Sclerosis Treatments / Kristopher J. Hult; 8. Physicians' Financial Incentives to Personalize Medicine / David H. Howard, Jason Hockenberry, and Guy David | |
| 505 | 8 | |a 9. Economic Dimensions of Personalized and Precision Medicine in Asia: Evidence from Breast Cancer Treatment in Taiwan / Jui-fen Rachel Lu, Karen Eggleston, and Joseph Tung-Chieh Chang10. The Value of Cytochrome P450 2C19 Pharmacogenomic Information for Patients Receiving Clopidogrel Therapy Following a Major Cardiovascular Event: Evidence from Geisinger / Rebecca A. Pulk, Jove Graham, Frank R. Lichtenberg, Daniel Maeng, Marc S. Williams, and Eric Wright; 11. Orphan Drug Designations as Valuable Intangible Assets for IPO Investors in Pharma-Biotech Companies / Philippe Gorry and Diego Useche | |
| 505 | 8 | |a ContributorsAuthor Index; Subject Index | |
| 588 | 0 | |a Online resource; title from digital title page (viewed on May 06, 2019). | |
| 520 | 8 | |a Personalized and precision medicine (PPM) - the targeting of therapies according to an individual's genetic, environmental, or lifestyle characteristics - is becoming an increasingly important approach in health care treatment and prevention. This volume explores the intersection of the scientific, clinical, and economic factors affecting the development of PPM, including its effects on the drug pipeline, on reimbursement of PPM diagnostics and treatments, and on funding of the requisite underlying research; and it examines recent empirical applications of PPM. | |
| 650 | 0 | |a Pharmacogenetics. |0 http://id.loc.gov/authorities/subjects/sh85100595 | |
| 650 | 0 | |a Precision medicine |x Economic aspects |z United States. | |
| 650 | 1 | 2 | |a Precision Medicine |x economics. |
| 650 | 2 | 2 | |a Pharmacogenetics |x methods |0 https://id.nlm.nih.gov/mesh/D010597Q000379 |
| 651 | 2 | |a United States |0 https://id.nlm.nih.gov/mesh/D014481 | |
| 650 | 2 | |a Pharmacogenetics |0 https://id.nlm.nih.gov/mesh/D010597 | |
| 650 | 6 | |a Pharmacogénétique. | |
| 650 | 6 | |a Médecine de précision |x Aspect économique |z États-Unis. | |
| 650 | 7 | |a MEDICAL |x Pharmacology. |2 bisacsh | |
| 650 | 7 | |a Pharmacogenetics |2 fast | |
| 651 | 7 | |a United States |2 fast |1 https://id.oclc.org/worldcat/entity/E39PBJtxgQXMWqmjMjjwXRHgrq | |
| 653 | |a genetic testing. | ||
| 653 | |a insurance coverage. | ||
| 653 | |a personalized medicine. | ||
| 653 | |a screening. | ||
| 653 | |a stratified medicine. | ||
| 653 | |a tailored medicine. | ||
| 653 | |a targeted medicine. | ||
| 700 | 1 | |a Berndt, Ernst R., |e editor. |0 http://id.loc.gov/authorities/names/n81109904 | |
| 700 | 1 | |a Goldman, Dana P. |q (Dana Paul), |d 1966- |e editor. |1 https://id.oclc.org/worldcat/entity/E39PBJtGVbxjVJQVKbm6fBtdwC |0 http://id.loc.gov/authorities/names/n93027345 | |
| 700 | 1 | |a Rowe, John |c (Professor of Health Policy), |e editor. |1 https://id.oclc.org/worldcat/entity/E39PCjH876W4rffWkwKDHgcqpK |0 http://id.loc.gov/authorities/names/no2018103913 | |
| 758 | |i has work: |a Economic dimensions of personalized and precision medicine (Text) |1 https://id.oclc.org/worldcat/entity/E39PCFJpBwyjQCPkCGqhdT3GBK |4 https://id.oclc.org/worldcat/ontology/hasWork | ||
| 776 | 0 | 8 | |i Print version: |t Economic dimensions of personalized and precision medicine. |d Chicago ; London : The University of Chicago Press, 2019 |z 9780226611068 |z 022661106X |w (DLC) 2018037553 |
| 830 | 0 | |a National Bureau of Economic Research conference report. |0 http://id.loc.gov/authorities/names/n00011926 | |
| 856 | 4 | 0 | |l FWS01 |p ZDB-4-EBA |q FWS_PDA_EBA |u https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=1941135 |3 Volltext |
| 938 | |a Askews and Holts Library Services |b ASKH |n AH34792397 | ||
| 938 | |a De Gruyter |b DEGR |n 9780226611235 | ||
| 938 | |a EBSCOhost |b EBSC |n 1941135 | ||
| 938 | |a Oxford University Press USA |b OUPR |n EDZ0002099201 | ||
| 938 | |a ProQuest Ebook Central |b EBLB |n EBL5735650 | ||
| 994 | |a 92 |b GEBAY | ||
| 912 | |a ZDB-4-EBA | ||
| 049 | |a DE-863 | ||
Datensatz im Suchindex
| DE-BY-FWS_katkey | ZDB-4-EBA-on1090397075 |
|---|---|
| _version_ | 1816882487888969728 |
| adam_text | |
| any_adam_object | |
| author2 | Berndt, Ernst R. Goldman, Dana P. (Dana Paul), 1966- Rowe, John (Professor of Health Policy) |
| author2_role | edt edt edt |
| author2_variant | e r b er erb d p g dp dpg j r jr |
| author_GND | http://id.loc.gov/authorities/names/n81109904 http://id.loc.gov/authorities/names/n93027345 http://id.loc.gov/authorities/names/no2018103913 |
| author_facet | Berndt, Ernst R. Goldman, Dana P. (Dana Paul), 1966- Rowe, John (Professor of Health Policy) |
| building | Verbundindex |
| bvnumber | localFWS |
| callnumber-first | R - Medicine |
| callnumber-label | RM301 |
| callnumber-raw | RM301.3.G45 E265 2019 |
| callnumber-search | RM301.3.G45 E265 2019 |
| callnumber-sort | RM 3301.3 G45 E265 42019 |
| callnumber-subject | RM - Therapeutics and Pharmacology |
| classification_rvk | QX 700 |
| collection | ZDB-4-EBA |
| contents | Intro; Contents; Acknowledgment; Introduction / Ernst R. Berndt, Dana P. Goldman, and John W. Rowe; 1. The Economic Value and Pricing of Personalized Medicine / Tomas J. Philipson; 2. Therapeutic Translation of Genomic Science: Opportunities and Limitations of GWAS / Manuel Hermosilla and Jorge Lemus; 3. The Value of Pharmacogenomic Information / John A. Graves, Zilu Zhou, Shawn Garbett, and Josh F. Peterson; 4. The Information Pharms Race and Competitive Dynamics of Precision Medicine: Insights from Game Theory / Ernst R. Berndt and Mark R. Trusheim 5. Characterizing the Drug Development Pipeline for Precision Medicines / Amitabh Chandra, Craig Garthwaite, and Ariel Dora Stern6. Cost Sharing in Insurance Coverage for Precision Medicine / Mark V. Pauly; 7. Measuring the Potential Health Impact of Personalized Medicine: Evidence from Multiple Sclerosis Treatments / Kristopher J. Hult; 8. Physicians' Financial Incentives to Personalize Medicine / David H. Howard, Jason Hockenberry, and Guy David 9. Economic Dimensions of Personalized and Precision Medicine in Asia: Evidence from Breast Cancer Treatment in Taiwan / Jui-fen Rachel Lu, Karen Eggleston, and Joseph Tung-Chieh Chang10. The Value of Cytochrome P450 2C19 Pharmacogenomic Information for Patients Receiving Clopidogrel Therapy Following a Major Cardiovascular Event: Evidence from Geisinger / Rebecca A. Pulk, Jove Graham, Frank R. Lichtenberg, Daniel Maeng, Marc S. Williams, and Eric Wright; 11. Orphan Drug Designations as Valuable Intangible Assets for IPO Investors in Pharma-Biotech Companies / Philippe Gorry and Diego Useche ContributorsAuthor Index; Subject Index |
| ctrlnum | (OCoLC)1090397075 |
| dewey-full | 615.7 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 615 - Pharmacology and therapeutics |
| dewey-raw | 615.7 |
| dewey-search | 615.7 |
| dewey-sort | 3615.7 |
| dewey-tens | 610 - Medicine and health |
| discipline | Wirtschaftswissenschaften Medizin |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>06294cam a2200865 i 4500</leader><controlfield tag="001">ZDB-4-EBA-on1090397075</controlfield><controlfield tag="003">OCoLC</controlfield><controlfield tag="005">20241004212047.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr cnu---unuuu</controlfield><controlfield tag="008">190322t20192019ilu ob 001 0 eng d</controlfield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">N$T</subfield><subfield code="b">eng</subfield><subfield code="e">rda</subfield><subfield code="e">pn</subfield><subfield code="c">N$T</subfield><subfield code="d">N$T</subfield><subfield code="d">EBLCP</subfield><subfield code="d">UKMGB</subfield><subfield code="d">YDXIT</subfield><subfield code="d">UKAHL</subfield><subfield code="d">STBDS</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">DEGRU</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">BRX</subfield><subfield code="d">OCLCO</subfield><subfield code="d">SFB</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">OCLCF</subfield><subfield code="d">OCLCA</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">OCLCA</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCL</subfield><subfield code="d">OCLCA</subfield><subfield code="d">OCLCL</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">DXU</subfield></datafield><datafield tag="015" ind1=" " ind2=" "><subfield code="a">GBB970705</subfield><subfield code="2">bnb</subfield></datafield><datafield tag="016" ind1="7" ind2=" "><subfield code="a">019360804</subfield><subfield code="2">Uk</subfield></datafield><datafield tag="019" ind1=" " ind2=" "><subfield code="a">1298410401</subfield><subfield code="a">1370503711</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780226611235</subfield><subfield code="q">(electronic book)</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">022661123X</subfield><subfield code="q">(electronic book)</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="z">9780226611068</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="z">022661106X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1090397075</subfield><subfield code="z">(OCoLC)1298410401</subfield><subfield code="z">(OCoLC)1370503711</subfield></datafield><datafield tag="037" ind1=" " ind2=" "><subfield code="a">org.bibliovault.9780226611235</subfield><subfield code="b">BiblioVault</subfield></datafield><datafield tag="043" ind1=" " ind2=" "><subfield code="a">n-us---</subfield></datafield><datafield tag="050" ind1=" " ind2="4"><subfield code="a">RM301.3.G45</subfield><subfield code="b">E265 2019</subfield></datafield><datafield tag="060" ind1=" " ind2="4"><subfield code="a">2019 H-417</subfield></datafield><datafield tag="060" ind1=" " ind2="4"><subfield code="a">WB 102.7</subfield></datafield><datafield tag="072" ind1=" " ind2="7"><subfield code="a">MED</subfield><subfield code="x">071000</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="082" ind1="7" ind2=" "><subfield code="a">615.7</subfield><subfield code="2">23</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">QX 700</subfield><subfield code="2">rvk</subfield><subfield code="0">(DE-625)rvk/142186</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">MAIN</subfield></datafield><datafield tag="245" ind1="0" ind2="0"><subfield code="a">Economic dimensions of personalized and precision medicine /</subfield><subfield code="c">edited by Ernst R. Berndt, Dana Goldman, and John Rowe.</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Chicago ;</subfield><subfield code="a">London :</subfield><subfield code="b">The University of Chicago Press,</subfield><subfield code="c">2019.</subfield></datafield><datafield tag="264" ind1=" " ind2="4"><subfield code="c">©2019</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">National Bureau of Economic Research conference report</subfield></datafield><datafield tag="504" ind1=" " ind2=" "><subfield code="a">Includes bibliographical references and index.</subfield></datafield><datafield tag="505" ind1="0" ind2=" "><subfield code="a">Intro; Contents; Acknowledgment; Introduction / Ernst R. Berndt, Dana P. Goldman, and John W. Rowe; 1. The Economic Value and Pricing of Personalized Medicine / Tomas J. Philipson; 2. Therapeutic Translation of Genomic Science: Opportunities and Limitations of GWAS / Manuel Hermosilla and Jorge Lemus; 3. The Value of Pharmacogenomic Information / John A. Graves, Zilu Zhou, Shawn Garbett, and Josh F. Peterson; 4. The Information Pharms Race and Competitive Dynamics of Precision Medicine: Insights from Game Theory / Ernst R. Berndt and Mark R. Trusheim</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">5. Characterizing the Drug Development Pipeline for Precision Medicines / Amitabh Chandra, Craig Garthwaite, and Ariel Dora Stern6. Cost Sharing in Insurance Coverage for Precision Medicine / Mark V. Pauly; 7. Measuring the Potential Health Impact of Personalized Medicine: Evidence from Multiple Sclerosis Treatments / Kristopher J. Hult; 8. Physicians' Financial Incentives to Personalize Medicine / David H. Howard, Jason Hockenberry, and Guy David</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">9. Economic Dimensions of Personalized and Precision Medicine in Asia: Evidence from Breast Cancer Treatment in Taiwan / Jui-fen Rachel Lu, Karen Eggleston, and Joseph Tung-Chieh Chang10. The Value of Cytochrome P450 2C19 Pharmacogenomic Information for Patients Receiving Clopidogrel Therapy Following a Major Cardiovascular Event: Evidence from Geisinger / Rebecca A. Pulk, Jove Graham, Frank R. Lichtenberg, Daniel Maeng, Marc S. Williams, and Eric Wright; 11. Orphan Drug Designations as Valuable Intangible Assets for IPO Investors in Pharma-Biotech Companies / Philippe Gorry and Diego Useche</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">ContributorsAuthor Index; Subject Index</subfield></datafield><datafield tag="588" ind1="0" ind2=" "><subfield code="a">Online resource; title from digital title page (viewed on May 06, 2019).</subfield></datafield><datafield tag="520" ind1="8" ind2=" "><subfield code="a">Personalized and precision medicine (PPM) - the targeting of therapies according to an individual's genetic, environmental, or lifestyle characteristics - is becoming an increasingly important approach in health care treatment and prevention. This volume explores the intersection of the scientific, clinical, and economic factors affecting the development of PPM, including its effects on the drug pipeline, on reimbursement of PPM diagnostics and treatments, and on funding of the requisite underlying research; and it examines recent empirical applications of PPM.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Pharmacogenetics.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh85100595</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Precision medicine</subfield><subfield code="x">Economic aspects</subfield><subfield code="z">United States.</subfield></datafield><datafield tag="650" ind1="1" ind2="2"><subfield code="a">Precision Medicine</subfield><subfield code="x">economics.</subfield></datafield><datafield tag="650" ind1="2" ind2="2"><subfield code="a">Pharmacogenetics</subfield><subfield code="x">methods</subfield><subfield code="0">https://id.nlm.nih.gov/mesh/D010597Q000379</subfield></datafield><datafield tag="651" ind1=" " ind2="2"><subfield code="a">United States</subfield><subfield code="0">https://id.nlm.nih.gov/mesh/D014481</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Pharmacogenetics</subfield><subfield code="0">https://id.nlm.nih.gov/mesh/D010597</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Pharmacogénétique.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Médecine de précision</subfield><subfield code="x">Aspect économique</subfield><subfield code="z">États-Unis.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL</subfield><subfield code="x">Pharmacology.</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Pharmacogenetics</subfield><subfield code="2">fast</subfield></datafield><datafield tag="651" ind1=" " ind2="7"><subfield code="a">United States</subfield><subfield code="2">fast</subfield><subfield code="1">https://id.oclc.org/worldcat/entity/E39PBJtxgQXMWqmjMjjwXRHgrq</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">genetic testing.</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">insurance coverage.</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">personalized medicine.</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">screening.</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">stratified medicine.</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">tailored medicine.</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">targeted medicine.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Berndt, Ernst R.,</subfield><subfield code="e">editor.</subfield><subfield code="0">http://id.loc.gov/authorities/names/n81109904</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Goldman, Dana P.</subfield><subfield code="q">(Dana Paul),</subfield><subfield code="d">1966-</subfield><subfield code="e">editor.</subfield><subfield code="1">https://id.oclc.org/worldcat/entity/E39PBJtGVbxjVJQVKbm6fBtdwC</subfield><subfield code="0">http://id.loc.gov/authorities/names/n93027345</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rowe, John</subfield><subfield code="c">(Professor of Health Policy),</subfield><subfield code="e">editor.</subfield><subfield code="1">https://id.oclc.org/worldcat/entity/E39PCjH876W4rffWkwKDHgcqpK</subfield><subfield code="0">http://id.loc.gov/authorities/names/no2018103913</subfield></datafield><datafield tag="758" ind1=" " ind2=" "><subfield code="i">has work:</subfield><subfield code="a">Economic dimensions of personalized and precision medicine (Text)</subfield><subfield code="1">https://id.oclc.org/worldcat/entity/E39PCFJpBwyjQCPkCGqhdT3GBK</subfield><subfield code="4">https://id.oclc.org/worldcat/ontology/hasWork</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Print version:</subfield><subfield code="t">Economic dimensions of personalized and precision medicine.</subfield><subfield code="d">Chicago ; London : The University of Chicago Press, 2019</subfield><subfield code="z">9780226611068</subfield><subfield code="z">022661106X</subfield><subfield code="w">(DLC) 2018037553</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">National Bureau of Economic Research conference report.</subfield><subfield code="0">http://id.loc.gov/authorities/names/n00011926</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="l">FWS01</subfield><subfield code="p">ZDB-4-EBA</subfield><subfield code="q">FWS_PDA_EBA</subfield><subfield code="u">https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=1941135</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">Askews and Holts Library Services</subfield><subfield code="b">ASKH</subfield><subfield code="n">AH34792397</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">De Gruyter</subfield><subfield code="b">DEGR</subfield><subfield code="n">9780226611235</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">EBSCOhost</subfield><subfield code="b">EBSC</subfield><subfield code="n">1941135</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">Oxford University Press USA</subfield><subfield code="b">OUPR</subfield><subfield code="n">EDZ0002099201</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">ProQuest Ebook Central</subfield><subfield code="b">EBLB</subfield><subfield code="n">EBL5735650</subfield></datafield><datafield tag="994" ind1=" " ind2=" "><subfield code="a">92</subfield><subfield code="b">GEBAY</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-4-EBA</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-863</subfield></datafield></record></collection> |
| geographic | United States https://id.nlm.nih.gov/mesh/D014481 United States fast https://id.oclc.org/worldcat/entity/E39PBJtxgQXMWqmjMjjwXRHgrq |
| geographic_facet | United States |
| id | ZDB-4-EBA-on1090397075 |
| illustrated | Not Illustrated |
| indexdate | 2024-11-27T13:29:24Z |
| institution | BVB |
| isbn | 9780226611235 022661123X |
| language | English |
| oclc_num | 1090397075 |
| open_access_boolean | |
| owner | MAIN DE-863 DE-BY-FWS |
| owner_facet | MAIN DE-863 DE-BY-FWS |
| physical | 1 online resource |
| psigel | ZDB-4-EBA |
| publishDate | 2019 |
| publishDateSearch | 2019 |
| publishDateSort | 2019 |
| publisher | The University of Chicago Press, |
| record_format | marc |
| series | National Bureau of Economic Research conference report. |
| series2 | National Bureau of Economic Research conference report |
| spelling | Economic dimensions of personalized and precision medicine / edited by Ernst R. Berndt, Dana Goldman, and John Rowe. Chicago ; London : The University of Chicago Press, 2019. ©2019 1 online resource text txt rdacontent computer c rdamedia online resource cr rdacarrier National Bureau of Economic Research conference report Includes bibliographical references and index. Intro; Contents; Acknowledgment; Introduction / Ernst R. Berndt, Dana P. Goldman, and John W. Rowe; 1. The Economic Value and Pricing of Personalized Medicine / Tomas J. Philipson; 2. Therapeutic Translation of Genomic Science: Opportunities and Limitations of GWAS / Manuel Hermosilla and Jorge Lemus; 3. The Value of Pharmacogenomic Information / John A. Graves, Zilu Zhou, Shawn Garbett, and Josh F. Peterson; 4. The Information Pharms Race and Competitive Dynamics of Precision Medicine: Insights from Game Theory / Ernst R. Berndt and Mark R. Trusheim 5. Characterizing the Drug Development Pipeline for Precision Medicines / Amitabh Chandra, Craig Garthwaite, and Ariel Dora Stern6. Cost Sharing in Insurance Coverage for Precision Medicine / Mark V. Pauly; 7. Measuring the Potential Health Impact of Personalized Medicine: Evidence from Multiple Sclerosis Treatments / Kristopher J. Hult; 8. Physicians' Financial Incentives to Personalize Medicine / David H. Howard, Jason Hockenberry, and Guy David 9. Economic Dimensions of Personalized and Precision Medicine in Asia: Evidence from Breast Cancer Treatment in Taiwan / Jui-fen Rachel Lu, Karen Eggleston, and Joseph Tung-Chieh Chang10. The Value of Cytochrome P450 2C19 Pharmacogenomic Information for Patients Receiving Clopidogrel Therapy Following a Major Cardiovascular Event: Evidence from Geisinger / Rebecca A. Pulk, Jove Graham, Frank R. Lichtenberg, Daniel Maeng, Marc S. Williams, and Eric Wright; 11. Orphan Drug Designations as Valuable Intangible Assets for IPO Investors in Pharma-Biotech Companies / Philippe Gorry and Diego Useche ContributorsAuthor Index; Subject Index Online resource; title from digital title page (viewed on May 06, 2019). Personalized and precision medicine (PPM) - the targeting of therapies according to an individual's genetic, environmental, or lifestyle characteristics - is becoming an increasingly important approach in health care treatment and prevention. This volume explores the intersection of the scientific, clinical, and economic factors affecting the development of PPM, including its effects on the drug pipeline, on reimbursement of PPM diagnostics and treatments, and on funding of the requisite underlying research; and it examines recent empirical applications of PPM. Pharmacogenetics. http://id.loc.gov/authorities/subjects/sh85100595 Precision medicine Economic aspects United States. Precision Medicine economics. Pharmacogenetics methods https://id.nlm.nih.gov/mesh/D010597Q000379 United States https://id.nlm.nih.gov/mesh/D014481 Pharmacogenetics https://id.nlm.nih.gov/mesh/D010597 Pharmacogénétique. Médecine de précision Aspect économique États-Unis. MEDICAL Pharmacology. bisacsh Pharmacogenetics fast United States fast https://id.oclc.org/worldcat/entity/E39PBJtxgQXMWqmjMjjwXRHgrq genetic testing. insurance coverage. personalized medicine. screening. stratified medicine. tailored medicine. targeted medicine. Berndt, Ernst R., editor. http://id.loc.gov/authorities/names/n81109904 Goldman, Dana P. (Dana Paul), 1966- editor. https://id.oclc.org/worldcat/entity/E39PBJtGVbxjVJQVKbm6fBtdwC http://id.loc.gov/authorities/names/n93027345 Rowe, John (Professor of Health Policy), editor. https://id.oclc.org/worldcat/entity/E39PCjH876W4rffWkwKDHgcqpK http://id.loc.gov/authorities/names/no2018103913 has work: Economic dimensions of personalized and precision medicine (Text) https://id.oclc.org/worldcat/entity/E39PCFJpBwyjQCPkCGqhdT3GBK https://id.oclc.org/worldcat/ontology/hasWork Print version: Economic dimensions of personalized and precision medicine. Chicago ; London : The University of Chicago Press, 2019 9780226611068 022661106X (DLC) 2018037553 National Bureau of Economic Research conference report. http://id.loc.gov/authorities/names/n00011926 FWS01 ZDB-4-EBA FWS_PDA_EBA https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=1941135 Volltext |
| spellingShingle | Economic dimensions of personalized and precision medicine / National Bureau of Economic Research conference report. Intro; Contents; Acknowledgment; Introduction / Ernst R. Berndt, Dana P. Goldman, and John W. Rowe; 1. The Economic Value and Pricing of Personalized Medicine / Tomas J. Philipson; 2. Therapeutic Translation of Genomic Science: Opportunities and Limitations of GWAS / Manuel Hermosilla and Jorge Lemus; 3. The Value of Pharmacogenomic Information / John A. Graves, Zilu Zhou, Shawn Garbett, and Josh F. Peterson; 4. The Information Pharms Race and Competitive Dynamics of Precision Medicine: Insights from Game Theory / Ernst R. Berndt and Mark R. Trusheim 5. Characterizing the Drug Development Pipeline for Precision Medicines / Amitabh Chandra, Craig Garthwaite, and Ariel Dora Stern6. Cost Sharing in Insurance Coverage for Precision Medicine / Mark V. Pauly; 7. Measuring the Potential Health Impact of Personalized Medicine: Evidence from Multiple Sclerosis Treatments / Kristopher J. Hult; 8. Physicians' Financial Incentives to Personalize Medicine / David H. Howard, Jason Hockenberry, and Guy David 9. Economic Dimensions of Personalized and Precision Medicine in Asia: Evidence from Breast Cancer Treatment in Taiwan / Jui-fen Rachel Lu, Karen Eggleston, and Joseph Tung-Chieh Chang10. The Value of Cytochrome P450 2C19 Pharmacogenomic Information for Patients Receiving Clopidogrel Therapy Following a Major Cardiovascular Event: Evidence from Geisinger / Rebecca A. Pulk, Jove Graham, Frank R. Lichtenberg, Daniel Maeng, Marc S. Williams, and Eric Wright; 11. Orphan Drug Designations as Valuable Intangible Assets for IPO Investors in Pharma-Biotech Companies / Philippe Gorry and Diego Useche ContributorsAuthor Index; Subject Index Pharmacogenetics. http://id.loc.gov/authorities/subjects/sh85100595 Precision medicine Economic aspects United States. Precision Medicine economics. Pharmacogenetics methods https://id.nlm.nih.gov/mesh/D010597Q000379 Pharmacogenetics https://id.nlm.nih.gov/mesh/D010597 Pharmacogénétique. Médecine de précision Aspect économique États-Unis. MEDICAL Pharmacology. bisacsh Pharmacogenetics fast |
| subject_GND | http://id.loc.gov/authorities/subjects/sh85100595 https://id.nlm.nih.gov/mesh/D010597Q000379 https://id.nlm.nih.gov/mesh/D014481 https://id.nlm.nih.gov/mesh/D010597 |
| title | Economic dimensions of personalized and precision medicine / |
| title_auth | Economic dimensions of personalized and precision medicine / |
| title_exact_search | Economic dimensions of personalized and precision medicine / |
| title_full | Economic dimensions of personalized and precision medicine / edited by Ernst R. Berndt, Dana Goldman, and John Rowe. |
| title_fullStr | Economic dimensions of personalized and precision medicine / edited by Ernst R. Berndt, Dana Goldman, and John Rowe. |
| title_full_unstemmed | Economic dimensions of personalized and precision medicine / edited by Ernst R. Berndt, Dana Goldman, and John Rowe. |
| title_short | Economic dimensions of personalized and precision medicine / |
| title_sort | economic dimensions of personalized and precision medicine |
| topic | Pharmacogenetics. http://id.loc.gov/authorities/subjects/sh85100595 Precision medicine Economic aspects United States. Precision Medicine economics. Pharmacogenetics methods https://id.nlm.nih.gov/mesh/D010597Q000379 Pharmacogenetics https://id.nlm.nih.gov/mesh/D010597 Pharmacogénétique. Médecine de précision Aspect économique États-Unis. MEDICAL Pharmacology. bisacsh Pharmacogenetics fast |
| topic_facet | Pharmacogenetics. Precision medicine Economic aspects United States. Precision Medicine economics. Pharmacogenetics methods United States Pharmacogenetics Pharmacogénétique. Médecine de précision Aspect économique États-Unis. MEDICAL Pharmacology. |
| url | https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=1941135 |
| work_keys_str_mv | AT berndternstr economicdimensionsofpersonalizedandprecisionmedicine AT goldmandanap economicdimensionsofpersonalizedandprecisionmedicine AT rowejohn economicdimensionsofpersonalizedandprecisionmedicine |